Aeonian Pharmaceuticals, Inc., a San Francisco Bay Area-based biopharmaceutical company, closed a seed financing round.
The round was led by Apollo Ventures. In connection with the investment, James Peyer, Managing Partner of Apollo Ventures, has joined Aeonian’s Board of Directors.
The company intends to use the funds to accelerate clinical development of its lead programs.
Led by Stelios Tzannis, President & Chief Executive Officer, Aeonian is engaged in the discovery and development of compounds harnessing the latest scientific breakthroughs to treat multiple diseases by addressing the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. The company’s lead compounds are therapeutics modulating the mTORC1 pathway in order to treat rare diseases.
Aeonian’s proprietary platform is supported by an extensive intellectual property portfolio, part of which has been obtained by assignment from the Buck Institute of Novato, California.